The Bioscience Association of Maine strongly opposes LD 1422, “An Act To Allow Maine Residents To Personally Import Medications as Permitted under the Federal Food, Drug, and Cosmetic Act”. This legislation, if passed, will present a great risk to the public health of Maine residents and will also open the State of Maine to additional costly and unnecessary litigation. BAM is of the opinion that the legislation outlined in LD 1422 is misguided and we feel inappropriately addresses the issue it purportedly seeks to remedy. Read full statement here
Related Posts
Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming
Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...
UNE retains R2 Research status, reinforcing leadership in scientific advancement
The University of New England has retained its status as one of the country’s leading research universities with the recent release...
Maine college students investigate health effects of forever chemicals
Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...